drtimos.bsky.social
@drtimos.bsky.social
230 followers 3 following 57K posts
Posts Media Videos Starter Packs
Signal or noise? > Informa Connect’s Trade and Channel Strategies >> Comment below! #strategy #competitiveintelligence #marketing #pharma #healthcare #productmarketing #biotech #pharmaceutical
Informa Connect’s Trade and Channel Strategies
Informa Connect’s Trade and Channel Strategies December 9-11, 2025W Philadelphia Exclusive Offer—Use promo 25DC10 to save 10%* The stakes have never been higher. With seismic shifts in distribution models, health policy and market access strategies, falling behind on critical trends could mean losing your competitive edge. If you’re a trade, channel, market access or brand professional, Informa Connect’s Trade and Channel Strategies is your must-attend event to stay ahead of the curve. Why attend? Informa Connect’s Trade and Channel Strategies celebrates two decades of excellence—Experts will explore the evolution of the landscape, unravel its complexities and showcase innovative pharmacy and distribution models shaped by shifting market dynamics. Walk away with actionable strategies to tackle the latest industry challenges. Why now? The US marketplace is in upheaval, with disruptions at both the pharmacy counter and across the supply chain. Policy changes, market fluctuations and new entrants, like GLP-1 therapies are reshaping the landscape. Traditional models are being replaced by innovative alternatives, leaving companies struggling to adapt. This conference offers critical insights into these changes and equips you to thrive in this evolving environment. What can you expect? The event features a stellar lineup of industry leaders, including Bill Roth of IntegriChain, who will deliver the keynote address, Navigating Disruption in Today’s Trade and Channel Marketplace. Other notable speakers include: * Christine Hummel, US Head, Trade & Channel Management, Sanofi * Ramita Tandon, Chief Biopharma Officer, Walgreens * Peter A. Arakelian, Head of Channel & Oncology Enterprise Accounts, EMD Serono * Martine Avello, Director, Channel and Distribution, BioMarin Pharmaceutical Inc * Thomas Scalone, Director, Trade Strategy and Operations, Bristol Myers Squibb * Stephanie Wirkes, Head of Distribution and Strategy Execution, Bayer * And more! Program highlights: * Navigate Regulatory Changes: Stay on top of DSCSA serialization, IRA impacts and PBM reforms that are reshaping the industry * Master Distribution Models: Explore the direct-to-patient revolution, limited distribution networks and innovative cold chain solutions for specialty pharmaceuticals * Optimize Market Access: Learn strategies to balance GTN optimization, payer negotiations and patient affordability * Leverage Technology: Discover how AI, digital tools and analytics are transforming trade strategies What attendees are saying: “For those of us responsible for navigating and developing specific strategy around this ever-changing marketplace in distribution channel management, this was a bullseye.” “Most valuable conference of the year to understand pharmacy and distribution related topics. There is no second.” “One of the best conferences I have ever attended. The speaker selection and topic covered from a strategic and tactical approach were extremely relevant to our business.” Exclusive Offer—Download the agenda and register today–Use your exclusive promo 25DC10 to save 10%* *Cannot be combined with other offers, promotions or applied to existing registration. Other restrictions may apply. The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can publish an event post on Drug Channels, please contact Paula Fein ([email protected]). © 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.        
dlvr.it
LucidQuest YouTube > Hematology Update – October 20, 2025: Orca-T Priority Review, Iopofosine CMA, MASP-3 deal and More: From EMA filing paths to FDA designations and market-shaping partnerships, this roundup spotlights the pivotal moves redefining… Subscribe for more! #LucidQuest #PharmaCI
Hematology Update – October 20, 2025: Orca-T Priority Review, Iopofosine CMA, MASP-3 deal and More
From EMA filing paths to FDA designations and market-shaping partnerships, this roundup spotlights the pivotal moves redefining hematology care. 💡 Key Highlights: ✅ Iopofosine I-131 earns EMA eligibility for a Conditional Marketing Authorization in post-BTKi Waldenström macroglobulinemia, supported by PRIME and CLOVER WaM data guidance. 🧪 Orca-T BLA accepted with FDA Priority Review for AML, ALL, and MDS, built on Precision-T results showing improved survival free of moderate to severe chronic GvHD compared with standard alloHSCT. 💵 HEMGENIX takes a step toward wider public access as CSL Behring signs a Letter of Intent with the pan-Canadian Pharmaceutical Alliance, enabling provincial listing processes for adult hemophilia B. 🧫 Sonrotoclax receives FDA Breakthrough Therapy Designation in relapsed or refractory mantle cell lymphoma, with Project Orbis participation to coordinate multi-agency reviews. 🧬 MNV-201 secures FDA Orphan Drug Designation for myelodysplastic syndrome, adding to existing Fast Track designations and supporting a mitochondrial cell therapy approach. 🧒 KRESLADI BLA resubmission accepted for severe LAD-I, backed by global Phase 1/2 data that report 100 percent survival at 12 months post infusion with fewer significant infections. 🤝 Novo Nordisk and Omeros sign an asset purchase and license for MASP-3 inhibitor zaltenibart, with total potential value up to 2.1 billion dollars, underscoring momentum in complement-pathway therapeutics. 🎯 Ideal for clinicians, researchers, and investors tracking regulatory milestones, access dynamics, and next-gen modalities across malignant and rare hematologic diseases. 📢 Stay Ahead in Hematology Research! ✅ Like, share, and subscribe for future updates on Hematology and specific diseases such as AML, MDS, and hemophilia ✅ Visit www.lqventures.com for expert healthcare insights and consulting services ✅ Contact LucidQuest at [email protected] for strategic guidance on Hematology innovations and clinical research 🔔 Turn on notifications so you never miss an update! #Hematology #Oncology #Waldenström #AML #ALL #MDS #HemophiliaB #GeneTherapy #CellTherapy #MantleCellLymphoma #MyelodysplasticSyndrome #Immunology #RareDisease #RegulatoryUpdates #DrugDevelopment #HealthcareConsulting #BiotechNews
www.youtube.com